| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5607942 | HARROW EYE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Mar, 2014
(10 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5607942 (Pediatric) | HARROW EYE | 7-(1-pyrrolidinyl)-3-quinolone- and - naphthyridone-carboxylic acid derivatives as antibacterial agents and feed additives |
Sep, 2014
(9 years ago) | |
| US7671070 | HARROW EYE | Method of treating ophthalmic infections with moxifloxacin compositions |
Sep, 2019
(4 years ago) | |
| US6716830 | HARROW EYE | Ophthalmic antibiotic compositions containing moxifloxacin |
Sep, 2019
(4 years ago) | |
|
US7671070 (Pediatric) | HARROW EYE | Method of treating ophthalmic infections with moxifloxacin compositions |
Mar, 2020
(4 years ago) | |
|
US6716830 (Pediatric) | HARROW EYE | Ophthalmic antibiotic compositions containing moxifloxacin |
Mar, 2020
(4 years ago) | |
| US9114168 | HARROW EYE | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(5 years from now) | |
| US8450311 | HARROW EYE | Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
May, 2029
(5 years from now) | |
Moxeza is owned by Harrow Eye.
Moxeza contains Moxifloxacin Hydrochloride.
Moxeza has a total of 8 drug patents out of which 6 drug patents have expired.
Expired drug patents of Moxeza are:
- US5607942*PED
- US7671070
- US6716830
- US7671070*PED
- US6716830*PED
- US5607942
Moxeza was authorised for market use on 19 November, 2010.
Moxeza is available in solution/drops;ophthalmic dosage forms.
Moxeza can be used as method of combating bacteria in a patient.
The generics of Moxeza are possible to be released after 29 May, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 19, 2013 |
| Pediatric Exclusivity(PED) | May 19, 2014 |
Drugs and Companies using MOXIFLOXACIN HYDROCHLORIDE ingredient
Market Authorisation Date: 19 November, 2010
Treatment: Method of combating bacteria in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
MOXEZA family patents
